

BASIC RESEARCH IN CANCER HEALTH DISPARITIES (R03/R21/R01)

Overview

These funding opportunities encourage grant applications investigating the biological/genetic contributors to cancer health disparities. In addition to expanding knowledge of the biological factors of cancer health disparities, these awards help expand available resources and tools (such as biospecimens, patient-derived models and methods) that are necessary to further conduct basic research in cancer health disparities.

Research Objectives

Applications should focus on basic mechanistic research to investigate biological factors associated with cancer health disparities, with a particular focus on the interplay of race/ethnicity and/or other social determinants with cancer biology. Proposed studies may include:

- Mechanistic studies of biological factors associated with cancer disparities;
- Development and testing of new methodologies and cancer models; and/or:
- Secondary data analyses.

Access to annotated clinical samples and/or patient-derived models are encouraged, as applicable. Examples of responsive research topics include:

- Genetic/epigenetic cancer susceptibility differences among racial/ethnic populations;
- Causal drivers of early-onset cancer in specific populations;
- Similarities and differences in cancer metabolism among racial/ethnic populations.

Mechanisms of Support

R03, R21 and R01 award mechanisms are supported by this funding opportunity:

- R03 awards are designed to support projects that can be carried out in a short period of time with limited resources.
- R21 awards are designed to support pilot and feasibility studies.
- R01 awards will fund more advanced projects that stem from preliminary studies/data.

Applications will be evaluated for scientific and technical merit by a Special Emphasis Panel using the stated review criteria in the funding opportunity announcement.

Submission Deadlines

R01: October 5, 2021; February 5, 2022; June 5, 2022; October 5, 2022; February 5, 2023; June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024

R21 and R03: October 16, 2021; February 16, 2022; June 16, 2022; October 16, 2022; February 16, 2023; June 16, 2023; October 16, 2023; February 16, 2024; June 16, 2024

Award Budget

R01 budgets are not limited, but need to be well justified.

R21 budgets are limited to \$275,000 direct costs for up to 2 years, with no more than \$200,000 in direct costs in any given year.

R03 budgets are limited to \$50,000 in direct costs per year for up to two years.

AT A GLANCE

Where Do I Learn More?

Visit the following links for the full text of these funding opportunity announcements. Contact Dr. Tiffany Wallace for more information:

Tiffany.Wallace@nih.gov.

- R01: <https://grants.nih.gov/grants/guide/pa-files/PAR-21-322.html>
- R21: <https://grants.nih.gov/grants/guide/pa-files/PAR-21-323.html>
- R03: <https://grants.nih.gov/grants/guide/pa-files/PAR-21-324.html>

Application Timeline for PAR-21-322 (R01), PAR-21-323 (R21) and PAR-21-324 (R03)

Potential applicants are strongly encouraged to contact the Scientific/Research Contact(s) listed in the funding opportunity announcements early in advance to submission. Please refer to the timeline below for key dates in the application process for the two submission periods.



Applications Due

February
June
October



Applications Reviewed

March
July
November



Advisory Council Review

January
May
October



Anticipated Start Date

April
July
December

Frequently Asked Questions (FAQs) for PAR-21-322 (R01), PAR-21-323 (R21) and PAR-21-324 (R03)

Are at least two populations required for investigation?

Cancer disparities are defined as **adverse differences** in cancer incidence, prevalence, mortality, survivorship, and/or burden of cancer, or related health conditions, that exist **among specific populations**. As such, a comparative research design is encouraged. Investigating a cancer site with a documented disparity (e.g. Triple Negative Breast Cancer) without investigating differences among populations is not within the scope of this FOA.

Is preliminary data required?

Preliminary data is not a requirement for the R21 or R03 mechanisms, however it is strongly encouraged.

Preliminary data is required for R01 applications.

Does the research strategy need to be translational?

As this FOA is focused upon basic research, immediate clinically translational potential of the proposed project is not a requirement for the proposed projects.